Henkel has launched a new class of 3D printing resins for healthcare applications under its leading Loctite brand. The broad portfolio of high performance photopolymers offers a range of biocompatibility standards from safe to touch parts to medical devices.
In addition to the established portfolio of Loctite 3D printing resins, the company innovates to deliver tailored formulations to fit the specific application requirements and market demands for optimised production.
Recently, the Henkel 3D printing facilities in Concord (laboratory) and Dixon (production) in California, USA, have achieved achieved the ISO 13485:2016 certification for medical applications. Henkel 3D printing resins are designed and manufactured in accordance with ISO 13485 quality management standards to ensure uniformity in design, development, production and delivery of medical devices. In Henkel’s case specifically, it covers the design and manufacturing of biocompatible resins and other materials used to produce non implantable medical devices.
Henkel resins are validated for use in approved workflows which enables customers to achieve consistent results in volume production while meeting the relevant biocompatibility measures. This process allows the company to technically engage with partners to assure results meeting the Technical Data Sheets and are biocompatible. Henkel can help customers derisk the path to launch a product in the healthcare market by developing products and validating workflows assuring regulatory requirements are met.
Having joined the magazine in 2012, Claire developed her knowledge of the industry through the numerous company visits, exhibitions and conferences she attended both in the UK and abroad.
Claire prides herself on keeping readers well informed and up to date with the latest industry news.